Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients. Issue 11 (26th April 2014)

• Record Type: Journal Article
• Authors: Warta, Rolf; Herold‐Mende, Christel; Chaisaingmongkol, Jittiporn; Popanda, Odilia; Mock, Andreas; Mogler, Carolin; Osswald, Florian; Herpel, Esther; Küstner, Sabine; Eckstein, Volker; Plass, Christoph; Plinkert, Peter; Schmezer, Peter; Dyckhoff, Gerhard
• Is Part Of: International journal of cancer. Volume 135:Issue 11(2014:Dec. 01)
• Page Start: 2727
• Page End: 2734
• Publication Date: 2014-04-26
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.28906
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Proteoglycans are often overexpressed in tumors and can be found on several normal and neoplastic stem cells. In this study, we analyzed in‐depth the role of CSPG4 in head and neck squamous cell carcinomas (HNSCC). Analysis of CSPG4 in a homogeneous study sample of HPV‐negative stage IVa HNSCCs revealed overexpression of protein and mRNA levels in a subgroup of HNSCC tumors and a significant association of high CSPG4 protein levels with poor survival. This could be validated in three publicly available microarray datasets. As a potential cause for upregulated CSPG4 expression, we identified DNA hypomethylation in a CpG‐island of the promoter region. Accordingly, we found an inverse correlation of methylation and patient outcome. Finally, CSPG4 re‐expression was achieved by demethylating treatment of highly methylated HNSCC cell lines establishing a direct link between methylation and CSPG4 expression. In conclusion, we identified CSPG4 as a novel biomarker in HNSCC on several biological levels and established a causative link between DNA methylation and CSPG4 protein and mRNA expression.</p> </abstract>